All enrolled people who gained at least one dose of zosuquidar or placebo throughout induction were being monitored to the event of adverse occasions (439 patients, 219 on zosuquidar and 210 on placebo). The most typical adverse activities had been associated with the duration of prolonged and sizeable myelosuppression as https://judahwvpnk.madmouseblog.com/8507781/glibornuride-can-be-fun-for-anyone